David A Knorr (David Knorr)

ORCID

Publication Activity (10 Years)

Years Active: 2020-2024
Publications (10 Years): 18

Top Venues

Cancer immunology research

Science translational medicine

bioRxiv : the preprint server for biology

Leukemia

Rockefeller University

This page only lists publications with an associated author ORCID identifier.

Affiliation History

Rockefeller University

United States

Instructor of Clinical Investigation

Publications

David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB Is an Immune Checkpoint Limiting the Activity of Treg-Targeting Antibodies in the Tumor Microenvironment. Cancer immunology research 12 (3) (2024)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Jeffrey L Wong, Patrick Smith, Juan Angulo-Lozano, Daniel Ranti, Bernard H Bochner, John P Sfakianos, Amir Horowitz, Jeffrey V Ravetch, David A Knorr
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. bioRxiv : the preprint server for biology (2023)
Jeffrey L Wong, Patrick Smith, Juan Angulo-Lozano, Daniel Ranti, Bernard H Bochner, John P Sfakianos, Amir Horowitz, Jeffrey V Ravetch, David A Knorr
IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer. bioRxiv : the preprint server for biology (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Scott Parker, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C Duncker, Aaron Briley, Adam M Swartz, James E Herndon, Yen-Rei A Yu, Roger E McLendon, Thomas F Tedder, Annick Desjardins, David M Ashley, Michael Dee Gunn, David S Enterline, David A Knorr, Ira H Pastan, Smita K Nair, Darell D Bigner, Vidyalakshmi Chandramohan
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science translational medicine 15 (682) (2023)
Scott Parker, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C Duncker, Aaron Briley, Adam M Swartz, James E Herndon, Yen-Rei A Yu, Roger E McLendon, Thomas F Tedder, Annick Desjardins, David M Ashley, Michael Dee Gunn, David S Enterline, David A Knorr, Ira H Pastan, Smita K Nair, Darell D Bigner, Vidyalakshmi Chandramohan
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science translational medicine 15 (682) (2023)
David A Knorr, Rom Leidner, Shawn Jensen, Ryan Meng, Andrew Jones, Carmen Ballesteros-Merino, R Bryan Bell, Maria Baez, David Sprott, Carlo Bifulco, Brian D Piening, Rony Dahan, Bernard A Fox, Jeffrey Ravetch
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies. bioRxiv : the preprint server for biology (2023)
Scott Parker, Charlotte McDowall, Luis Sanchez-Perez, Cristina Osorio, Patrick C Duncker, Aaron Briley, Adam M Swartz, James E Herndon, Yen-Rei A Yu, Roger E McLendon, Thomas F Tedder, Annick Desjardins, David M Ashley, Michael Dee Gunn, David S Enterline, David A Knorr, Ira H Pastan, Smita K Nair, Darell D Bigner, Vidyalakshmi Chandramohan
Immunotoxin-αCD40 therapy activates innate and adaptive immunity and generates a durable antitumor response in glioblastoma models. Science translational medicine 15 (682) (2023)
David A Knorr, Rom Leidner, Shawn Jensen, Ryan Meng, Andrew Jones, Carmen Ballesteros-Merino, R Bryan Bell, Maria Baez, David Sprott, Carlo Bifulco, Brian D Piening, Rony Dahan, Bernard A Fox, Jeffrey Ravetch
FcyRIIB is a novel immune checkpoint in the tumor microenvironment limiting activity of Treg-targeting antibodies. bioRxiv : the preprint server for biology (2023)
David A Knorr, Lucas Blanchard, Rom S Leidner, Shawn M Jensen, Ryan Meng, Andrew T Jones, Carmen Ballesteros-Merino, Richard B Bell, Maria Baez, Alessandra Marino, David Sprott, Carlo B Bifulco, Brian D Piening, Rony Dahan, Juan C Osorio, Bernard A Fox, Jeffrey V Ravetch
FcγRIIB is an immune checkpoint limiting the activity of Treg-targeting antibodies in the tumor microenvironment. Cancer immunology research (2023)
Ramin Sedaghat Herati, David A Knorr, Laura A Vella, Luisa Victoria Silva, Lakshmi Chilukuri, Sokratis A Apostolidis, Alexander C Huang, Alexander Muselman, Sasikanth Manne, Oliva Kuthuru, Ryan P Staupe, Sharon A Adamski, Senthil Kannan, Raj K Kurupati, Hildegund C J Ertl, Jeffrey L Wong, Stylianos Bournazos, Suzanne McGettigan, Lynn M Schuchter, Ritesh R Kotecha, Samuel A Funt, Martin H Voss, Robert J Motzer, Chung-Han Lee, Dean F Bajorin, Tara C Mitchell, Jeffrey V Ravetch, E John Wherry
PD-1 directed immunotherapy alters Tfh and humoral immune responses to seasonal influenza vaccine. Nature immunology 23 (8) (2022)
Priyanka Lakshmanan, Heena Asnani, David A Knorr
Central Diabetes Insipidus Induced by Acute Myeloid Leukemia with DNMT3A Mutation. Case reports in endocrinology 2022 (2022)
Lindsey Elizabeth Roeker, David A Knorr, Meghan C Thompson, Mariely Nivar, Sonia Lebowitz, Nicole Peters, Isaac Deonarine, Saddia Momotaj, Saumya Sharan, Vanessa Chanlatte, Bianca Hampton, Liana Butala, Lindsay Amato, Angela Richford, Jessica Lunkenheimer, Kristen Battiato, Carissa Laudati, Anthony R Mato
COVID-19 vaccine efficacy in patients with chronic lymphocytic leukemia. Leukemia 35 (9) (2021)
Christopher S Garris, Jeffrey L Wong, Jeffrey V Ravetch, David A Knorr
Dendritic cell targeting with Fc-enhanced CD40 antibody agonists induces durable antitumor immunity in humanized mouse models of bladder cancer. Science translational medicine 13 (594) (2021)
Lindsey Elizabeth Roeker, David A Knorr, Melissa S Pessin, Lakshmi V Ramanathan, Meghan C Thompson, Lori A Leslie, Andrew D Zelenetz, Anthony R Mato
Anti-SARS-CoV-2 antibody response in patients with chronic lymphocytic leukemia. Leukemia 34 (11) (2020)

David A Knorr.css-eqlu8i{font-size:small;padding-left:4px;} (David Knorr)

Publication Activity (10 Years)

Top Topics

Top Venues

David A Knorr (David Knorr)